Journal Mobile Options
Table of Contents
Vol. 214, No. 4, 2007
Issue release date: April 2007
Dermatology 2007;214:325–327
(DOI:10.1159/000100883)

Hidradenitis Suppurativa and Zinc: A New Therapeutic Approach

A Pilot Study

Brocard A. · Knol A.-C. · Khammari A. · Dréno B.
aDepartment of Dermatology and bLaboratory of Dermato-Immunology, INSERM U601, CHU Hôtel-Dieu, Nantes, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Hidradenitis suppurativa (Verneuil’s disease) is a chronic suppurative dermatosis involving apocrine glands with a severe impact on the quality of life, which is enhanced by the fact that the drugs usually prescribed are poorly effective. Objective: We discuss a new therapeutic approach based on zinc salts. Methods: We performed a pilot study on 22 patients, mainly from grade I or II in Hurley’s classification. All included patients had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. They were then treated with 90 mg of zinc gluconate per day (15 mg zinc per Rubozinc® capsule). Results: We observed a clinical response in all patients, with 8 complete remissions (CR) and 14 partial remissions (PR). When CR was obtained, the treatment was progressively decreased (average of 3.5 capsules/day); 4/22 patients experienced side-effects, mainly gastro-intestinal. Conclusion: Zinc salts could provide a new therapeutic alternative for the treatment of hidradenitis suppurativa.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Jemec GB, Heidenheim M, Nielsen NH: The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–194.
  2. Sartorius K, Lapins J, Jalal S, Emtestam L, Hedberg M: Bacteraemia in patients with hidradenitis suppurativa undergoing carbon dioxide laser surgery: detection and quantification of bacteria by lysis-filtration. Dermatology 2006;213:305–312.
  3. Yu CC, Cook MG: Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990;122:763–769.
  4. Brocard A: Maladie de Verneuil et zinc: une nouvelle approche thérapeutique; thèse médecine, Service de dermatologie, CHU Nantes, avril 2005.
  5. Dreno B, Amblard P, Agache P, Sirot S, Litoux P: Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol (Stockh) 1989;69:541–543.
  6. Dreno B, Moyse D, Alirezai M, Amblard P, Auffret N, Beylot C, Bodokh I, Chivot M, Daniel F, Humbert P, Meynadier J, Poli F, and private practice dermatologists coordinated by the Acne Research and Study Group (GREA): Multicenter randomised comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001;203:135–140.
  7. Dreno B, Trossaert M, Boiteau HL, Litoux P: Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol 1992;72:250–252.
  8. Chvapil M, Stankova L, Zukoski C IV, Zukoski C III: Inhibition of some functions of polymorphonuclear leukocytes by in vitro zinc. J Lab Clin Med 1977;89:135–146.
  9. Gueniche A, Viac J, Lizard G, Charveron M, Schmitt D, et al: Protective effect of zinc on keratinocyte activation markers induced by interferon or nickel. Acta Derm Venereol 1995;75:19–23.
  10. Sainte Marie I, Jumbou O, Tenaud I, Dréno B: Comparative study of the in vitro inflammatory activity of three nickels salts on keratinocytes. Acta Derm Venereol 1998;78:169–172.
  11. Sugimoto Y, Lopez-Solachez I, Labrie F, Luu-The V: Cations inhibit specifically type I 5α-reductase found in human skin. J Invest Dermatol 1995;104:775–778.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00